• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Should All Growth Restricted Fetuses Be Managed the Same?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • FGR is defined as EFW <10th percentile
  • SGA is defined as BW below < 10th percentile for gestational age
  • There is limited data on early onset FGR, especially severe FGR, defined as <5 percentile
  • Zhang-Rutledge et al. (Journal of Ultrasound in Medicine, 2018) assessed whether severity of fetal growth restriction impacted neonatal and pregnancy outcomes

METHODS:

  • Retrospective cohort study
    • Singleton and nonanomalous
    • EFW ≤10th percentile at 18 to 24 weeks’ gestation
  • The cohort was divided into fetuses with estimated fetal weight
    • <5th percentile
    • Between the 5th to 10th percentiles
  • Ultrasound
    • Measurements based on Hadlock
    • Midgestation: 18w0d-24w6d
  • FGR protocol
    • Serial growth scans every 3 to 4 weeks
    • EFW <10th percentile: Weekly antenatal testing at 32 weeks’ gestation
    • EFW <5th percentile: Weekly antenatal testing at 28 weeks
    • Abnormal umbilical artery Doppler: Antenatal testing is increased to twice weekly
    • Delivery based on NICHD/SMFM guidelines
  • Primary outcome
    • Whether early-onset severe FGR is associated with SGA compared to fetuses measuring in the 5th to 10th percentiles
  • Secondary outcomes
    • Compare groups for differences in maternal and neonatal complications

RESULTS:

  • 254 FGR fetuses
    • Overall incidence of midgestational FGR in the study population was 2.5%
    • Severe FGR: 91
    • 5th to 10th percentiles: 163
  • Fetuses with severe FGR were more likely to be born SGA vs 5th to 10th percentiles
    • Relative risk (RR) 2.82 (95% CI, 1.52-5.23; P = .001)
  • Fetuses with severe FGR, compared to 5th to 10th percentiles had higher rates of
    • Hypertensive disorders of pregnancy (RR 1.79; P = .04)
      • 22% vs 12.3%
    • Abnormal umbilical artery Doppler waveforms (RR 6.27; P = .01)
      • 7.7% vs 1.2%
    • Labor induction (RR 1.45; P = .002)
      • 65.9% vs 45.4%
    • Neonatal intensive care unit admission (RR 1.73; P = .02)
      • 28.5% vs 16.6%
    • Apgar scores of less than 7 at 1 minute (RR 2.05; P = .04) but not significantly different at 5 minutes

CONCLUSION:

  • The authors suggested that severe FGR at midgestation may be more reflective of pathologic restriction vs constitutional restriction while those fetuses between the 5th and 10th percentile may be constitutionally small with less risk to the pregnancy
  • Different management algorithms for serial surveillance may be indicated

Learn More – Primary Sources:

Significance and Outcomes of Fetal Growth Restriction Below the 5th Percentile Compared to the 5th to 10th Percentiles on Midgestation Growth Ultrasonography

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Maternal Depression or Stress Affect Fetal Growth?
Cesarean or Vaginal Delivery for Preterm Fetal Growth Restriction?
RCOG or ACOG for Predicting Small for Gestational Age Birth?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site